CD8 + T cells in preventing HIV infection and disease

AIDS

Volumn 26, Issue 10, 2012, Pages 1281-1292

  McDermott, Adrian B ^a   Koup, Richard A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

CD8 + T cell; HIV disease; HIV infection; HIV vaccine

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR7; EPITOPE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ALLELE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELL MIGRATION; CYTOKINE RELEASE; CYTOTOXICITY; DISEASE CONTROL; DISEASE COURSE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRACELLULAR SIGNALING; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HIV; HIV INFECTIONS; HUMANS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84862744172     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328353bcaf     Document Type: Review

References (182)

1. WHO. http://www.who.int/hiv/pub/progress-report2011/en/index.html.
2. De Cock KM, Jaffe HW, Curran JW. The evolving epidemiology of HIV/AIDS. AIDS 2012; 26:1205-1213.
3. Shattock RJ, Warren M, McCormack S, Hankins CA. AIDS. Turning the tide against HIV. Science 2011; 333:42-43.
4. Karim SS, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 2011; 378:e23-e25.
5. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral preexposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378:279-281.
6. Excler JL, Rida W, Priddy F, Gilmour J, McDermott AB, Kamali A, et al. AIDS vaccines and preexposure prophylaxis: is synergy possible?. AIDS Res Hum Retroviruses 2011; 27:669-680.
7. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10:11-23.
8. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4R T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759. (Pubitemid 39299461)
9. Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, Margolick JB, et al. Biphasic decay of latently infected CD4RT cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:1636-1642.
10. Levy JA. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 2009; 23:147-160.
11. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011; 62:127-139.
12. Loffredo JT, Friedrich TC, Leon EJ, Stephany JJ, Rodrigues DS, Spencer SP, et al. CD8R T cells from SIV elite controller macaques recognize Mamu-BM08-bound epitopes and select for widespread viral variation. PLoS One 2007; 2:e1152.
13. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-416. (Pubitemid 47418678)
14. Munoz A, Kirby AJ, He YD, Margolick JB, Visscher BR, Rinaldo CR, et al. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4R lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:496-505.
15. Alexander L, Weiskopf E, Greenough TC, Gaddis NC, Auerbach MR, Malim MH, et al. Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol 2000; 74:4361-4376. (Pubitemid 30214444)
16. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, et al. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol 2008; 82:8422-8430.
17. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007; 81:2508-2518.
18. Mens H, Kearney M, Wiegand A, Shao W, Schonning K, Gerstoft J, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010; 84:12971-12981.
19. O'Connell KA, Hegarty RW, Siliciano RF, Blankson JN. Viral suppression of multiple escape mutants by de novo CD8(R) T cell responses in a human immunodeficiency virus-1 infected elite suppressor. Retrovirology 2011; 8:63.
20. Zhang N, Bevan MJ. CD8(R) T cells: foot soldiers of the immune system. Immunity 2011; 35:161-168.
21. Gerlach C, van Heijst JW, Swart E, Sie D, Armstrong N, Kerkhoven RM, et al. One naive T cell, multiple fates in CD8RT cell differentiation. J Exp Med 2010; 207:1235-1246.
22. Kaech SM, Ahmed R. Memory CD8R T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001; 2:415-422. (Pubitemid 33706139)
23. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-712.
24. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4:225-234. (Pubitemid 36322131)
25. Hanke T. Vehicles for genetic vaccines against human immunodeficiency virus: induction of T cell-mediated immune responses. Curr Mol Med 2001; 1:123-135. (Pubitemid 33772973)
26. Moss B. Use of vaccinia virus vectors for development of AIDS vaccines. AIDS 1988; 2 (Suppl 1):S103-S105. (Pubitemid 19042845)
27. Robinson HL, Amara RR. T cell vaccines for microbial infections. Nat Med 2005; 11:S25-S32. (Pubitemid 40562301)
28. Welsh RM, Selin LK, Szomolanyi-Tsuda E. Immunological memory to viral infections. Annu Rev Immunol 2004; 22:711-743. (Pubitemid 38680439)
29. Li Q, Skinner PJ, Ha SJ, Duan L, Mattila TL, Hage A, et al. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 2009; 323:1726-1729.
30. Stock AT, Jones CM, Heath WR, Carbone FR. Cutting edge: central memory T cells do not show accelerated proliferation or tissue infiltration in response to localized herpes simplex virus-1 infection. J Immunol 2006; 177:1411-1415. (Pubitemid 44092472)
31. Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010; 115:1678-1689.
32. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8R cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110. (Pubitemid 24258634)
33. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655. (Pubitemid 24183063)
34. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279:2103-2106. (Pubitemid 28196353)
35. Reimann KA, Tenner-Racz K, Racz P, Montefiori DC, Yasutomi Y, Lin W, et al. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol 1994; 68:2362-2370. (Pubitemid 24091915)
36. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998; 72:164-169. (Pubitemid 28048825)
37. Connor RI, Montefiori DC, Binley JM, Moore JP, Bonhoeffer S, Gettie A, et al. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 1998; 72:7501-7509. (Pubitemid 28377882)
38. Schmitz JE. Control of viremia in simian immunodeficiency virus infection byCD8Rlymphocytes. Science 1999; 283:857-860.
39. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic rise in plasma viremia after CD8(R) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189:991-998. (Pubitemid 29149355)
40. Hay CM, Ruhl DJ, Basgoz NO, Wilson CC, Billingsley JM, DePasquale MP, et al. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol 1999; 73:5509-5519. (Pubitemid 29274834)
41. Draenert R, Verrill CL, Tang Y, Allen TM, Wurcel AG, Boczanowski M, et al. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J Virol 2004; 78:630-641. (Pubitemid 38067584)
42. Walker CM, Moody DJ, Stites DP, Levy JA. CD8Rlymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234:1563-1566. (Pubitemid 17125280)
43. Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, Adelsberger JW, et al. Major expansion of CD8R T cells with a predominant V beta usage during the primary immune response to HIV. Nature 1994; 370:463-467. (Pubitemid 24263551)
44. Chakrabarti L, Guyader M, Alizon M, Daniel MD, Desrosiers RC, Tiollais P, et al. Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature 1987; 328:543-547. (Pubitemid 17098358)
45. Hu SL. Nonhuman primate models for AIDS vaccine research. Curr Drug Targets Infect Disord 2005; 5:193-201.
46. Valentine LE, Watkins DI. Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol 2008; 16:605-611.
47. Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 2006; 18:399-405. (Pubitemid 43947575)
48. Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, Weinfurter JT, et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 2008; 205:2537-2550.
49. Friedrich TC, Valentine LE, Yant LJ, Rakasz EG, Piaskowski SM, Furlott JR, et al. Subdominant CD8R T-cell responses are involved in durable control of AIDS virus replication. J Virol 2007; 81:3465-3476. (Pubitemid 46456655)
50. Check E. AIDS vaccines: back to 'plan A'. Nature 2003; 423:912-914.
51. Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206:1117-1134.
52. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105:7552-7557. (Pubitemid 351830056)
53. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 1988; 336:484-487.
54. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997; 94:1890-1895. (Pubitemid 27113932)
55. Furtado MR, Balachandran R, Gupta P, Wolinsky SM. Analysis of alternatively spliced human immunodeficiency virus type-1 mRNA species, one of which encodes a novel tat-env fusion protein. Virology 1991; 185:258-270.
56. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3:205-211. (Pubitemid 27064706)
57. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-390.
58. Chen ZW, Craiu A, Shen L, Kuroda MJ, Iroku UC, Watkins DI, et al. Simian immunodeficiency virus evades a dominant epitope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I. J Immunol 2000; 164:6474-6479. (Pubitemid 30408831)
59. Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, et al. De novo generation of escape variant-specific CD8R T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 2005; 79:12952-12960. (Pubitemid 41433214)
60. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206:1253-1272.
61. O'Connor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, Dodds E, et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002; 8:493-499. (Pubitemid 34546752)
62. O'Connor D, Friedrich T, Hughes A, Allen TM, Watkins D. Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection. Immunol Rev 2001; 183:115-126. (Pubitemid 34015443)
63. O'Connor DH, McDermott AB, Krebs KC, Dodds EJ, Miller JE, Gonzalez EJ, et al. A dominant role for CD8R-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol 2004; 78:14012-14022. (Pubitemid 39612797)
64. Bernardin F, Kong D, Peddada L, Baxter-Lowe LA, Delwart E. Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes. J Virol 2005; 79:11523-11528. (Pubitemid 41170695)
65. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, Carlson JM, et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 2008; 205:1009-1017. (Pubitemid 351679677)
66. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, Cullen C, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 2004; 10:275-281. (Pubitemid 38667618)
67. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10:282-289. (Pubitemid 38667619)
68. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, Reddy S, et al. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-BM5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J Virol 2007; 81:8346-8351. (Pubitemid 47101520)
69. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193:375-386.
70. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 2007; 81:12382-12393. (Pubitemid 350085852)
71. Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, Desouza I, et al. Escape and compensation from early HLAB57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol 2007; 81:12608-12618. (Pubitemid 350085874)
72. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80:3617-3623.
73. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, et al. Human immunodeficiency virus type 1-specific CD8R T-cell responses during primary infection are major determinants of the viral set point and loss of CD4R T cells. J Virol 2009; 83:7641-7648.
74. Vanderford TH, Bleckwehl C, Engram JC, Dunham RM, Klatt NR, Feinberg MB, et al. Viral CTL escape mutants are generated in lymph nodes and subsequently become fixed in plasma and rectal mucosa during acute SIV infection of macaques. PLoS Pathog 2011; 7:e1002048.
75. Dong T, Zhang Y, Xu KY, Yan H, James I, Peng Y, et al. Extensive HLA-driven viral diversity following a narrowsource HIV-1 outbreak in rural China. Blood 2011; 118:98-106.
76. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, et al. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 2009; 5:e1000414.
77. Li B, Gladden AD, Altfeld M, Kaldor JM, Cooper DA, Kelleher AD, et al. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol 2007; 81:193-201. (Pubitemid 44975160)
78. Brumme ZL, Tao I, Szeto S, Brumme CJ, Carlson JM, Chan D, et al. Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. AIDS 2008; 22:1277-1286.
79. Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, Goodman R, et al. Protective HLA class I alleles that restrict acute-phase CD8R T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J Virol 2009; 83:1845-1855.
80. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(R) T cell response against HIV-1. PLoS Med 2006; 3:e403.
81. Ganusov VV, Goonetilleke N, Liu MK, Ferrari G, Shaw GM, McMichael AJ, et al. Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J Virol 2011; 85:10518-10528.
82. Brumme ZL, Li C, Miura T, Sela J, Rosato PC, Brumme CJ, et al. Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr 2011; 56:100-108.
83. Appay V, Douek DC, Price DA. CD8R T cell efficacy in vaccination and disease. Nat Med 2008; 14:623-628. (Pubitemid 351809548)
84. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947. (Pubitemid 47301321)
85. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-411. (Pubitemid 26193012)
86. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and BM35-CwM04 disadvantage. Science 1999; 283:1748-1752.
87. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA BM5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97:2709-2714. (Pubitemid 30159236)
88. Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, Enz AM, et al. The high-frequency major histocompatibility complex class I allele Mamu-BM17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 2006; 80:5074-5077.
89. Loffredo JT, Maxwell J,Qi Y, Glidden CE, Borchardt GJ, Soma T, et al. Mamu-BM08-positive macaques control simian immunodeficiency virus replication. J Virol 2007; 81:8827-8832. (Pubitemid 47242856)
90. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769-775.
91. Zhang ZQ, Fu TM, Casimiro DR, Davies ME, Liang X, Schleif WA, et al. Mamu-AM01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol 2002; 76:12845-12854. (Pubitemid 35386968)
92. Fadda L, O'Connor GM, Kumar S, Piechocka-Trocha A, Gardiner CM, Carrington M, et al. Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules. J Virol 2011; 85:5970-5974.
93. Brackenridge S, Evans EJ, Toebes M, Goonetilleke N, Liu MK, di Gleria K, et al. An early HIV mutation within an HLA-BM57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1. J Virol 2011; 85:5415-5422.
94. Ploquin MJ-Y, Jacquelin B, Jochems SP, Barré-Sinoussi F, Mü ller-Trutwin MC. Innate immunity in the control of HIV/AIDS: recent advances and open questions. AIDS 2012; 26:1269-1279.
95. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3:212-217. (Pubitemid 27064707)
96. Ammaranond P, Zaunders J, Satchell C, van Bockel D, Cooper DA, Kelleher AD. A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1. AIDS Res Hum Retroviruses 2005; 21:395-397. (Pubitemid 40800455)
97. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, Karthas N, et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J Virol 2004; 78:8927-8930. (Pubitemid 39025159)
98. Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, Teaberry V, et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA 2005; 102:4512-4517. (Pubitemid 40397143)
99. Weinfurter JT, May GE, Soma T, Hessell AJ, Leon EJ, Macnair CE, et al. Macaque long-term nonprogressors resist superinfection with multiple CD8R T cell escape variants of simian immunodeficiency virus. J Virol 2011; 85:530-541.
100. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, et al. HLA-B57/BM5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 2009; 83:2743-2755.
101. McDermott AB, O'Connor DH, Fuenger S, Piaskowski S, Martin S, Loffredo J, et al. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirusboosted and DNA-primed Mamu-AM01-positive rhesus macaques. J Virol 2005; 79:15556-15566. (Pubitemid 43032337)
102. Maness NJ, Yant LJ, Chung C, Loffredo JT, Friedrich TC, Piaskowski SM, et al. Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-BM17-positive Simian immunodeficiency virus-infected rhesus macaques. J Virol 2008; 82:5245-5254. (Pubitemid 351705233)
103. Bailey JR, Williams TM, Siliciano RF, Blankson JN. Maintenance of viral suppression in HIV-1-infected HLA-BM57R elite suppressors despite CTL escape mutations. J Exp Med 2006; 203:1357-1369. (Pubitemid 43736603)
104. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-339. (Pubitemid 34087556)
105. Vojnov L, Martins MA, Almeida JR, Ende Z, Rakasz EG, Reynolds MR, et al. GagCM9-specific CD8R T cells expressing limited public TCR clonotypes do not suppress SIV replication in vivo. PLoS One 2011; 6:e23515.
106. Price DA, Asher TE, Wilson NA, Nason MC, Brenchley JM, Metzler IS, et al. Public clonotype usage identifies protective Gag-specific CD8R T cell responses in SIV infection. J Exp Med 2009; 206:923-936.
107. Iglesias MC, Almeida JR, Fastenackels S, van Bockel DJ, Hashimoto M, Venturi V, et al. Escape from highly effective public CD8RT-cell clonotypes by HIV. Blood 2011; 118:2138-2149.
108. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, et al. Superior control of HIV-1 replication by CD8R T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204:2473-2485. (Pubitemid 47529331)
109. Miles JJ, Douek DC, Price DA. Bias in the alphabeta T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol Cell Biol 2011; 89:375-387.
110. Allen TM, Jing P, Calore B, Horton H, O'Connor DH, Hanke T, et al. Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol 2002; 76:10507-10511.
111. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8R T cells. Blood 2006; 107:4781-4789. (Pubitemid 43882629)
112. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci USA 2005; 102:7239-7244. (Pubitemid 40696363)
113. Arrode G, Finke JS, Zebroski H, Siegal FP, Steinman RM. CD8R T cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses. Eur J Immunol 2005; 35:159-170. (Pubitemid 40123862)
114. Horton H, Frank I, Baydo R, Jalbert E, Penn J, Wilson S, et al. Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol 2006; 177:7406-7415. (Pubitemid 44715111)
115. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8R T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068. (Pubitemid 35363659)
116. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010; 6:e1000917.
117. Williams LD, Bansal A, Sabbaj S, Heath SL, Song W, Tang J, et al. Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers. J Virol 2011; 85:2316-2324.
118. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104:6776-6781. (Pubitemid 47175577)
119. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, et al. Lytic granule loading of CD8R T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29:1009-1021.
120. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, Koelle DM, et al. ProtectiveHIV-specific CD8RT cells evade Treg cell suppression. Nat Med 2011; 17:989-995.
121. Weiss L, Piketty C, Assoumou L, Didier C, Caccavelli L, Donkova-Petrini V, et al. Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy. PLoS One 2010; 5:e11659.
122. Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 2011; 6:e15924.
123. Weiss L, Letimier FA, Carriere M, Maiella S, Donkova-Petrini V, Targat B, et al. In vivo expansion of naive and activated CD4RCD25RFOXP3R regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci USA 2010; 107:10632-10637.
124. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, et al. PD-1 is a regulator of virus-specific CD8R T cell survival in HIV infection. J Exp Med 2006; 203:2281-2292. (Pubitemid 44498363)
125. Petrovas C, Chaon B, Ambrozak DR, Price DA, Melenhorst JJ, Hill BJ, et al. Differential association of programmed death-1 and CD57 with ex vivo survival of CD8R T cells in HIV infection. J Immunol 2009; 183:1120-1132.
126. Zhang JY, Zhang Z, Wang X, Fu JL, Yao J, Jiao Y, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8R T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007; 109:4671-4678. (Pubitemid 46827757)
127. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354. (Pubitemid 44435155)
128. Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, Meier A, et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8R T cells. PLoS Med 2008; 5:e100.
129. Mudd PA, Watkins DI. Understanding animal models of elite control:windowsoneffectiveimmuneresponses againstimmunodeficiency viruses. Curr Opin HIV AIDS 2011; 6:197-201.
130. Porichis F, Kaufmann DE. HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS 2011; 6:174-180.
131. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS 2011; 6:181-187.
132. Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS 2012; 26:1293-1302.
133. Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, et al. Heterogeneity in HIVsuppression byCD8 T cells from HIV controllers: association with Gag-specificCD8 T cell responses. J Immunol 2009; 182:7828-7837.
134. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, Bean AT, et al. Gag-specific CD8R T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007; 178:2746-2754. (Pubitemid 46333151)
135. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8R T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53. (Pubitemid 46067385)
136. Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-AM01-negative rhesus monkeys. J Virol 2005; 79:12321-12331. (Pubitemid 41346094)
137. Kawada M, Tsukamoto T, Yamamoto H, Iwamoto N, Kurihara K, Takeda A, et al. Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol 2008; 82:10199-10206.
138. Julg B,WilliamsKL, Reddy S, Bishop K, Qi Y, Carrington M, et al. Enhanced anti-HIV functional activity associated with Gagspecific CD8 T-cell responses. J Virol 2010; 84:5540-5549.
139. Riviere Y, McChesney MB, Porrot F, Tanneau-Salvadori F, Sansonetti P, Lopez O, et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 1995; 11:903-907.
140. Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, et al. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8R T cells: correlation with viral load. J Virol 2004; 78:3233-3243. (Pubitemid 38568263)
141. Nqoko B, Day CL, Mansoor N, De Kock M, Hughes EJ, Hawkridge T, et al. HIV-specific gag responses in early infancy correlate with clinical outcome and inversely with viral load. AIDS Res Hum Retroviruses 2011; 27:1311-1316.
142. Allen TM, Mortara L, Mothe BR, Liebl M, Jing P, Calore B, et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002; 76:4108-4112. (Pubitemid 34250576)
143. Yang OO, Sarkis PT, Ali A, Harlow JD, Brander C, Kalams SA, et al. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med 2003; 197:1365-1375. (Pubitemid 36617783)
144. van Baalen CA, Guillon C, van Baalen M, Verschuren EJ, Boers PH, Osterhaus AD, et al. Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur J Immunol 2002; 32:2644-2652.
145. Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, Vogt VM, et al. The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 2004; 11:672-675. (Pubitemid 38823535)
146. Sacha JB, Chung C, Reed J, Jonas AK, Bean AT, Spencer SP, et al. Pol-specific CD8R T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I downregulation. J Virol 2007; 81:11703-11712. (Pubitemid 47623802)
147. Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol 2007; 81:8258-8269. (Pubitemid 47101511)
148. Quinones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, Vanham G, et al. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000; 74:9222-9233.
149. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 2009; 5:e1000365.
150. Rolland M, Nickle DC, Mullins JI. HIV-1 group M conserved elements vaccine. PLoS Pathog 2007; 3:e157.
151. Kong WP, Wu L, Wallstrom TC, Fischer W, Yang ZY, Ko SY, et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009; 83:2201-2215.
152. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, Fischer W, et al. Mosaic vaccines elicit CD8R T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010; 16:324-328.
153. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010; 16:319-323.
154. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
155. See http://www.hvtn.org/science/step-buch.html.
156. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-ofconcept STEP Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
157. Li F, FinnefrockAC,Dubey SA, KorberBT, Szinger J,Cole S, et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the STEP study. PLoS One 2011; 6:e20479.
158. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012; 122:359-367.
159. West EE, Youngblood B, Tan WG, Jin HT, Araki K, Alexe G, et al. Tight regulation of memory CD8(R) T cells limits their effectiveness during sustained high viral load. Immunity 2011; 35:285-298.
160. Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, Gilbert P, et al. An Ad5-vectored HIV-1 vaccine elicits cellmediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the STEP study). J Infect Dis 2011; 203:765-772.
161. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-470.
162. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811-817.
163. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010; 5:428-434.
164. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293-299.
165. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523-527.
166. Woodland DL. Jump-starting the immune system: primeboosting comes of age. Trends Immunol 2004; 25:98-104. (Pubitemid 38167491)
167. Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 2002; 76:7187-7202. (Pubitemid 41246232)
168. Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S, et al. DNA/MVA vaccine for HIV type 1: effects of codonoptimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses 2004; 20:1335-1347. (Pubitemid 40065929)
169. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74. (Pubitemid 32289126)
170. Casimiro DR, Cox K, Tang A, Sykes KJ, Feng M, Wang F, et al. Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge. J Virol 2010; 84:2996-3003.
171. Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79:15547-15555. (Pubitemid 43032336)
172. Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, Furlott J, et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006; 80:5875-5885. (Pubitemid 43849165)
173. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 2009; 83:6508-6521.
174. Liu J, Keele BF, Li H, Keating S, Norris PJ, Carville A, et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010; 84:10406-10412.
175. Hudgens MG, Gilbert PB, Mascola JR, Wu CD, Barouch DH, Self SG. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J Infect Dis 2009; 200:609-613.
176. McDermott AB, Mitchen J, Piaskowski S, De Souza I, Yant LJ, Stephany J, et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J Virol 2004; 78:3140-3144. (Pubitemid 38314372)
177. Winstone N, Wilson AJ, Morrow G, Boggiano C, Chiuchiolo MJ, Lopez M, et al. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA primeviral vector boost vaccine regimen. J Virol 2011; 85:9578-9587.
178. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91.
179. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralizationresistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93.
180. Remmerswaal EB, Havenith SH, Idu MM, van Leeuwen EM, van Donselaar KA, Ten Brinke A, et al. Human virus-specific effector-type T cells accumulate in blood but not in lymph nodes. Blood 2012; 119:1702-1712.
181. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012; 63:95-111.
182. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, Siess D, et al. Evasion of CD8R T cells is critical for superinfection by cytomegalovirus. Science 2010; 328:102-106.